TriveniBio
PrivateLast Round
Series C
Jun 17, 2026
Est. Valuation
$390.53M
Total Funding Raised
$272M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
TriveniBio operates in Healthcare & Life Sciences and is based in Watertown, Massachusetts. Its latest recorded funding round was a Series C round in June 2026.
TriveniBio is a clinical-stage biotechnology company developing novel antibody-based therapies for immunological and inflammatory disorders using a genetics-informed approach.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TriveniBio Comparables
Compare TriveniBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Attovia Therapeutics | 77% | |
| Roche Holding | 75% | |
| Bionyra Pharma | 74% |
For institutional investors. Book with your work email.
TriveniBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jun 17, 2026 | ||||
| Series B | Oct 2, 2024 | ||||
| Series A | Oct 26, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
TriveniBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series C |
| Fidelity Management & Research Company | Series B |
| Deep Track Capital | Series C, Series B |
| OrbiMed | Series B, Series A |
| Cormorant Capital | Series A |
| Invus Opportunities | Series B, Series A |
| Viking Global Investors | Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 17, 2026
$65M round led by Janus Henderson Group and Ascenta Capital
- Nov 1, 2025
Developing an IL-13 targeting asset for atopic dermatitis.
For institutional investors. Book with your work email.
TriveniBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about TriveniBio's valuation, stock price, and market status.
Is TriveniBio a public or private company?
TriveniBio is a private company.
What is the current stock price of TriveniBio?
TriveniBio is a private company, so its shares have no public market price. Caplight tracks TriveniBio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is TriveniBio worth (valuation)?
TriveniBio's valuation is estimated at $390.5M based on funding round data.
Can I buy TriveniBio stock?
TriveniBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was TriveniBio's last funding round?
TriveniBio's most recent funding round was Series C on June 17, 2026.
Who are the main investors in TriveniBio?
Key investors in TriveniBio include Janus Henderson Group, Cormorant Capital, Atlas Venture, Goldman Sachs Alternatives, Cormorant Asset Management.
Will TriveniBio IPO soon?
No public IPO plans have been announced for TriveniBio.
How can I track TriveniBio secondary market activity?
Caplight tracks bids, offers, and trades in TriveniBio's shares on secondary markets.